AstraZeneca, Theragnostics sign PARPi development agreement

5th September 2019 Uncategorised 0

The licensing agreement enables the company’s “freedom to operate globally in the diagnostic field of certain selected radionuclide-labelled PARPi”.

More: AstraZeneca, Theragnostics sign PARPi development agreement
Source: News